CO2017002166A2 - Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa - Google Patents

Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa

Info

Publication number
CO2017002166A2
CO2017002166A2 CONC2017/0002166A CO2017002166A CO2017002166A2 CO 2017002166 A2 CO2017002166 A2 CO 2017002166A2 CO 2017002166 A CO2017002166 A CO 2017002166A CO 2017002166 A2 CO2017002166 A2 CO 2017002166A2
Authority
CO
Colombia
Prior art keywords
interleukin
polypeptide
fusion protein
fusion proteins
alpha receptor
Prior art date
Application number
CONC2017/0002166A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Malek
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017002166(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Miami filed Critical Univ Miami
Publication of CO2017002166A2 publication Critical patent/CO2017002166A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
CONC2017/0002166A 2014-08-06 2017-03-03 Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa CO2017002166A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
CO2017002166A2 true CO2017002166A2 (es) 2017-05-19

Family

ID=53836871

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002166A CO2017002166A2 (es) 2014-08-06 2017-03-03 Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa

Country Status (22)

Country Link
US (2) US20170233448A1 (ru)
EP (1) EP3177307A1 (ru)
JP (3) JP6723982B2 (ru)
KR (1) KR102653758B1 (ru)
CN (2) CN107074967B (ru)
AU (3) AU2015301071C1 (ru)
BR (1) BR112017001940A2 (ru)
CA (1) CA2957273C (ru)
CL (1) CL2017000284A1 (ru)
CO (1) CO2017002166A2 (ru)
EA (2) EA202091342A3 (ru)
IL (2) IL250007B (ru)
MA (2) MA40721A (ru)
MX (1) MX2017001062A (ru)
MY (1) MY180831A (ru)
PE (1) PE20170503A1 (ru)
PH (1) PH12017500042A1 (ru)
SA (1) SA517380842B1 (ru)
SG (2) SG11201700706WA (ru)
TN (1) TN2017000020A1 (ru)
WO (1) WO2016022671A1 (ru)
ZA (1) ZA201700245B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2931114A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CA3084262A1 (en) 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3768700A1 (en) * 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
AR115024A1 (es) 2018-03-28 2020-11-18 Bristol Myers Squibb Co PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO
EP3941935A1 (en) * 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036A (zh) 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM標的化免疫寛容
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
EP4045077A1 (en) * 2019-10-18 2022-08-24 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
AU2020407233A1 (en) 2019-12-20 2022-08-18 Regeneron Pharmaceuticals, Inc. Novel IL2 agonists and methods of use thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
WO2023154894A2 (en) * 2022-02-11 2023-08-17 Alkermes Pharma Ireland Limited Compositions and methods for cancer immunotherapy
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298144A3 (en) * 1994-12-28 2006-05-31 University of Kentucky Research Foundation Murine monoclonal anti-idiotype antibody 3H1
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
EP1447451A4 (en) * 2001-09-28 2006-06-07 Dnavec Research Inc MAMMALIAN INFECTIVE, EPITOPEED BETA2m CODING VIRUS VECTOR AND ITS USE
MX2007014474A (es) * 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
MA40721A (fr) 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
CL2017000284A1 (es) 2017-11-17
SA517380842B1 (ar) 2021-12-26
EA201790063A1 (ru) 2017-06-30
EA035956B1 (ru) 2020-09-04
CN107074967B (zh) 2021-06-08
PE20170503A1 (es) 2017-05-11
CA2957273C (en) 2023-03-14
JP6723982B2 (ja) 2020-07-15
AU2022204034A1 (en) 2022-07-14
AU2015301071A1 (en) 2017-02-02
JP2021000084A (ja) 2021-01-07
MX2017001062A (es) 2017-07-14
JP2017523789A (ja) 2017-08-24
MA40721A (fr) 2017-06-13
EA202091342A2 (ru) 2020-11-30
IL250007A0 (en) 2017-03-30
ZA201700245B (en) 2024-06-26
KR102653758B1 (ko) 2024-04-04
CN107074967A (zh) 2017-08-18
SG10201913695PA (en) 2020-03-30
MA40094A1 (fr) 2021-09-30
IL275944B (en) 2022-02-01
PH12017500042A1 (en) 2017-05-22
JP7272663B2 (ja) 2023-05-12
TN2017000020A1 (en) 2018-07-04
CA2957273A1 (en) 2016-02-11
AU2020203352A1 (en) 2020-07-02
WO2016022671A1 (en) 2016-02-11
MA40094B1 (fr) 2022-05-31
EP3177307A1 (en) 2017-06-14
CN113912737A (zh) 2022-01-11
KR20170030646A (ko) 2017-03-17
IL250007B (en) 2020-07-30
AU2015301071C1 (en) 2020-07-02
AU2020203352B2 (en) 2022-03-10
EA202091342A3 (ru) 2020-12-30
JP2023099045A (ja) 2023-07-11
IL275944A (en) 2020-08-31
US20230079120A1 (en) 2023-03-16
BR112017001940A2 (pt) 2017-11-28
SG11201700706WA (en) 2017-02-27
MY180831A (en) 2020-12-10
US20170233448A1 (en) 2017-08-17
AU2015301071B2 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CL2018000340A1 (es) Construcciones con un dominio sirp-alfa o sus variantes.
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201990017A1 (ru) Антитела к миостатину и способы их применения
DOP2017000258A (es) Proteínas de fusión
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
UY36021A (es) Proteìnas fc multimèricas
BR112016015512A2 (pt) proteínas quiméricas de fator viii e suas utilizações
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
BR112019023071A2 (pt) proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
CL2019001136A1 (es) Inmunoglobulinas y usos de estas.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
EA201890914A1 (ru) Доставка белка бактериями
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.
CL2016002068A1 (es) Perfeccionamiento de la expresion de proteinas recombinantes con el uso de un sistema de retencion de celulas basado en membrana
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.